Influenza Diagnostic Market Report 2025

This Influenza Diagnostic market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The influenza diagnostic market size has grown strongly in recent years. It will grow from $2.73 billion in 2024 to $2.89 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to e-commerce growth, labor shortages, automation and productivity, supply chain optimization, rising costs of labor, government support for automation and robotics.

The influenza diagnostic market size is expected to see strong growth in the next few years. It will grow to $4.01 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to customization and scalability, environmental and sustainability goals, need to improve operational efficiency, need to meet the demands of modern supply chain dynamics. Major trends in the forecast period include advanced technology integration, robotic picking and packing, autonomous mobile robots, real-time data and analytics, ai-driven decision making, collaborative robots, advancements in robotic technology.

Rapid diagnostic tests are anticipated to drive the growth of the influenza diagnostic market. These tests are medical tools designed to quickly confirm or rule out a condition or disease, addressing the rising demand for accurate and timely results in healthcare. Rapid influenza diagnostic tests (RIDTs) are particularly valued for their ability to detect influenza viral antigens within 10-15 minutes, offering moderate sensitivity (50-70%). For example, in July 2024, the Australian Institute of Health and Welfare reported that diagnostic imaging services increased from 28.4 million in 2021-22 to 29.7 million in 2022-23. Consequently, the growing adoption of rapid diagnostic tests is propelling the influenza diagnostic market.

Increasing funding for research on influenza diagnostics is a key factor driving market growth. Understanding the public health impact of influenza requires comprehensive research into the virus and its effects on individuals and populations. Accelerating scientific advancements with significant public health implications is essential. Public and private health organizations, researchers, healthcare professionals, and biopharmaceutical companies have been increasing investments in research funding or grants to mitigate the risks of pandemic influenza. For example, in October 2024, the Australian Government, through the Department of Health and Aged Care, allocated $95 million to combat avian influenza, aimed at protecting agriculture, wildlife, and the economy. As a result, increasing research funding is propelling the influenza diagnostic market.

Key players in the influenza diagnostic market are actively innovating and developing groundbreaking products like the Lucira COVID-19 & Flu Home Test, allowing rapid simultaneous qualitative detection. This single-use at-home test kit enables users to obtain results from self-collected nasal swab samples in approximately 30 minutes. An example of such innovation is the approval received by Pfizer Inc., a US-based pharmaceutical company, in February 2023 for the Lucira by Pfizer COVID-19 & Flu Home Test. This test is capable of detecting both influenza A and B (commonly known as the flu) and SARS-CoV-2, the virus responsible for COVID-19.

The utilization of rapid influenza diagnostic tests (RIDTs) in influenza diagnostics is increasingly prevalent. RIDTs, which are immunoassays, identify the presence of influenza A and B viral nucleoprotein antigens in respiratory specimens, providing a qualitative result (positive or negative). These tests deliver outcomes within a clinically relevant timeframe of approximately 15 minutes and are particularly effective in diagnosing patients with influenza-like symptoms, especially within the first four days of symptom onset. The growing favor for RIDTs is attributed to their user-friendly nature and swift diagnostic capabilities.

In February 2024, Thyrocare Technologies Limited, an India-based healthcare company, acquired Think Health Diagnostic Private Limited for an undisclosed amount. The acquisition expands Thyrocare’s service portfolio, enabling broader customer outreach and strengthening its market share in the diagnostic sector. This integration also introduces at-home ECG testing alongside blood diagnostics, establishing Thyrocare as a comprehensive provider for premedical and annual health checkups. Think Health Diagnostic Private Limited is an India-based home healthcare services company specializing in telehealth, laboratory testing, and pharmacy services.

The diagnosis of influenza, commonly known as the flu, involves employing various tests to detect the presence of the influenza virus. These diagnostic methods include viral culture, serology, rapid antigen testing, reverse transcription-polymerase chain reaction (RT-PCR), immunofluorescence assays, and rapid molecular assays. Influenza is caused by three primary types of the influenza virus such as type A, type B, and type C. Its symptoms typically include fever, sore throat, cough, body ache, fatigue, and headache. The market for influenza diagnostics encompasses the revenues generated by entities involved in conducting tests for the detection of the influenza virus.

The conventional diagnostic tests for influenza comprise rapid influenza diagnostic tests (RIDT), viral culture, DFA, serological assays, and other tests. Rapid influenza diagnostic tests (RIDTs) are immunoassays capable of identifying the presence of influenza A and B viral nucleoprotein antigens in respiratory samples, offering a qualitative outcome (positive or negative). Molecular diagnostic tests encompass a range of methods such as Reverse Transcription Polymerase Chain Reaction (RT-PCR), Isothermal Nucleic Acid Amplification Tests (INAAT), loop-mediated isothermal-based amplification assays, transcription-mediated isothermal-based amplification assays, and other isothermal nucleic acid amplification tests. These tests are employed by hospitals, clinical laboratories, diagnostic reference laboratories, academic/research institutes, and other end users.

The influenza diagnostic market research report is one of a series of new reports that provides influenza diagnostic market statistics, including influenza diagnostic industry global market size, regional shares, competitors with a influenza diagnostic market share, detailed influenza diagnostic market segments, market trends and opportunities, and any further data you may need to thrive in the influenza diagnostic industry. This influenza diagnostic market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major companies operating in the influenza diagnostic market include F. Hoffmann-La Roche Ltd., Quidel Corporation, Thermo Fisher Scientific Inc., Abbott Laboratories, Hologic Inc., Becton Dickinson and Company, DiaSorin SpA, Luminex Corporation, Meridian Bioscience Inc., GenMark Diagnostics Inc., SA Scientific Ltd., Sekisui Diagnostics LLC, bioMérieux Inc., Danaher Corporation, Siemens Healthineers AG, Coris Bioconcept Sprl, Mast Group, Elitech Technology lnc., Analytik Jena AG, altona Diagnostics GmbH, Tecan Trading AG, Genome Diagnostics Pvt Ltd., Germaine Laboratories Inc., Response Biomedical Corporation, TAUNS Laboratories Inc., TRUPCR Europe Ltd., Quest Diagnostics Inc., Labcorp Employer Services Inc., TotalWellness Ltd., Health Advocate Inc., Optum Global Solutions Private Ltd.

North America was the largest region in the influenza diagnostics market in 2024. Western Europe was the second largest region in the influenza diagnostics market. The regions covered in the influenza diagnostic market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the influenza diagnostic market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The influenza diagnostic market includes revenue earned by test kit and reagents, and other products. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.